These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12187323)

  • 1. The clinical development of the bryostatins.
    Clamp A; Jayson GC
    Anticancer Drugs; 2002 Aug; 13(7):673-83. PubMed ID: 12187323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma.
    Varterasian ML; Pemberton PA; Hulburd K; Rodriguez DH; Murgo A; Al-Katib AM
    Invest New Drugs; 2001; 19(3):245-7. PubMed ID: 11561682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
    Weitman S; Langevin AM; Berkow RL; Thomas PJ; Hurwitz CA; Kraft AS; Dubowy RL; Smith DL; Bernstein M
    Clin Cancer Res; 1999 Sep; 5(9):2344-8. PubMed ID: 10499603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bryostatin-1: a novel PKC inhibitor in clinical development.
    Kortmansky J; Schwartz GK
    Cancer Invest; 2003; 21(6):924-36. PubMed ID: 14735696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee.
    Philip PA; Rea D; Thavasu P; Carmichael J; Stuart NS; Rockett H; Talbot DC; Ganesan T; Pettit GR; Balkwill F
    J Natl Cancer Inst; 1993 Nov; 85(22):1812-8. PubMed ID: 8230261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review.
    Raghuvanshi R; Bharate SB
    Curr Top Med Chem; 2020; 20(12):1124-1135. PubMed ID: 32209043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
    Jayson GC; Crowther D; Prendiville J; McGown AT; Scheid C; Stern P; Young R; Brenchley P; Chang J; Owens S
    Br J Cancer; 1995 Aug; 72(2):461-8. PubMed ID: 7640233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
    Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
    Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells.
    May WS; Sharkis SJ; Esa AH; Gebbia V; Kraft AS; Pettit GR; Sensenbrenner LL
    Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8483-7. PubMed ID: 3317410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of bryostatin 20: a symbiont-produced chemical defense for larvae of the host bryozoan, Bugula neritina.
    Lopanik N; Gustafson KR; Lindquist N
    J Nat Prod; 2004 Aug; 67(8):1412-4. PubMed ID: 15332866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic Bryostatin Derivatives from the South China Sea Bryozoan Bugula neritina.
    Yu HB; Yang F; Li YY; Gan JH; Jiao WH; Lin HW
    J Nat Prod; 2015 May; 78(5):1169-73. PubMed ID: 25932671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemistry and clinical biology of the bryostatins.
    Mutter R; Wills M
    Bioorg Med Chem; 2000 Aug; 8(8):1841-60. PubMed ID: 11003129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies.
    Marshall JL; Bangalore N; El-Ashry D; Fuxman Y; Johnson M; Norris B; Oberst M; Ness E; Wojtowicz-Praga S; Bhargava P; Rizvi N; Baidas S; Hawkins MJ
    Cancer Biol Ther; 2002; 1(4):409-16. PubMed ID: 12432257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of murine melanoma with bryostatin 1.
    Schuchter LM; Esa AH; May S; Laulis MK; Pettit GR; Hess AD
    Cancer Res; 1991 Jan; 51(2):682-7. PubMed ID: 1985785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bryostatins trigger human polymorphonuclear neutrophil and monocyte oxidative metabolism: association with in vitro antineoplastic activity.
    Esa AH; Warren JT; Hess AD; May WS
    Res Immunol; 1995; 146(6):351-61. PubMed ID: 8719659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the antitumor activity of bryostatins 1, 5, and 8.
    Kraft AS; Woodley S; Pettit GR; Gao F; Coll JC; Wagner F
    Cancer Chemother Pharmacol; 1996; 37(3):271-8. PubMed ID: 8529289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
    Grant S; Roberts J; Poplin E; Tombes MB; Kyle B; Welch D; Carr M; Bear HD
    Clin Cancer Res; 1998 Mar; 4(3):611-8. PubMed ID: 9533528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study.
    Gonzalez R; Ebbinghaus S; Henthorn TK; Miller D; Kraft AS
    Melanoma Res; 1999 Dec; 9(6):599-606. PubMed ID: 10661772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    Varterasian ML; Mohammad RM; Shurafa MS; Hulburd K; Pemberton PA; Rodriguez DH; Spadoni V; Eilender DS; Murgo A; Wall N; Dan M; Al-Katib AM
    Clin Cancer Res; 2000 Mar; 6(3):825-8. PubMed ID: 10741703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development.
    Ruan BF; Zhu HL
    Curr Med Chem; 2012; 19(16):2652-64. PubMed ID: 22506770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.